Results 181 to 190 of about 277,018 (298)

Macrophage–Derived Ferritin Exacerbates Silica‐Induced Pulmonary Fibrosis via PIK3R2‐Mediated Fibroblast Differentiation

Advanced Science, EarlyView.
This study identifies ferritin as a pivotal mediator of silica‐induced pulmonary fibrosis. Macrophage‐derived ferritin drives fibroblast‐to‐myofibroblast differentiation via the PIK3R2/SMAD pathway, while ferritin knockdown alleviates fibrosis. These findings define ferritin as both a biomarker and pathogenic driver, highlighting ferritin‐PIK3R2 ...
Liqun Wang, Xuxi Chen, Hongying Quan, Rui Qian, Shuyu Gong, Qiurong He, Ying Gao, Ajia Axi, Manyu Zhao, Qin Zhang, Ling Zhang, Lijun Peng, Xin Sun, Ben Zhang, Yuqin Yao   +14 more
wiley   +1 more source

Integrative exercise and nutrition strategies in leukemia survivorship: implications for cognitive function and quality of life. [PDF]

Cancer Cell Int
Yuan S, Ye Q, Qin R, Rajabi S.
europepmc   +1 more source

Trojan Horse Strategy: How Biomimetic Nanomedicine Remodels the Tumor Microenvironment

Advanced Science, EarlyView.
This review focuses on biomimetic nanomedicines for tumor microenvironment (TME) remodeling, covering their diverse biomimetic types, design principles, and mechanisms of immune cell reprogramming and reversal of immunosuppressive microenvironments, with particular emphasis on their application in synergistic immunotherapy.
Wanrong Wang, Siqi Mu, Juan Zhang, Guisong Shan, Xueqian Li, Ran Wang, Tao Guo, Xiaoyan He   +7 more
wiley   +1 more source

Unraveling Intractable Headache in Acute Myeloid Leukemia With Coexisting Migraines and Chiari Malformation. [PDF]

Cureus
Singla L, Austin HW.
europepmc   +1 more source

Cellular Identity Crisis: RD3 Loss Fuels Plasticity and Immune Silence in Progressive Neuroblastoma

Advanced Science, EarlyView.
Researchers discovered that therapy‐induced loss of RD3 protein in neuroblastoma triggers a dangerous shift: cancer cells become more stem‐like, invasive, and resistant to treatment while evading immune detection. RD3 loss suppresses antigen presentation and boosts immune checkpoints, creating an immune‐silent environment.
Poorvi Subramanian, Sreenidhi Mohanvelu, Sheeja Aravindan, Afsana Parveen Jahir Hussain, Sivasubramani Narayanan, Sabir Salim, Loganayaki Periyasamy, Natarajan Aravindan   +7 more
wiley   +1 more source

NSG-S mice for acute myeloid leukemia, yes. For myelodysplastic syndrome, no

Haematologica, 2018
Emmanuel Griessinger, Michael Andreeff
doaj   +1 more source

Correction: RUNX1A isoform is overexpressed in acute myeloid leukemia and is associated with FLT3 internal tandem duplications. [PDF]

Cancer Gene Ther
Cumbo C, Tarantini F, Parciante E, Anelli L, Zagaria A, Biondi G, Caratozzolo MF, Orsini P, Coccaro N, Tota G, Redavid I, Conserva MR, Minervini A, Minervini CF, Gagliardi VP, Delia M, Marzano F, Telegrafo C, Cox SN, Natalicchio A, Balech B, Tullo A, Gentile M, Giorgino F, Specchia G, Musto P, Albano F.   +26 more
europepmc   +1 more source

Targeting DAP5 Disrupts Alternate Mode of Translational Initiation in Tregs and Potentiates Antitumor Immunity

Advanced Science, EarlyView.
Regulatory T cells (Tregs) suppress antitumor immunity. This study identifies that the translation scaffold DAP5/eIF4G2 is upregulated in tumor‐infiltrating Tregs (ti‐Tregs). DAP5 mediates an alternate translation mode to sustain CD25 and MCL‐1 expression, which is critical for ti‐Treg stability and survival in the tumor microenvironment.
Xiaojiang Lai, Guihong Pan, Xixi Feng, Jun Zhang, Yunxia Li, Shanmeizi Zhao, Zhenming Lin, Yun Feng, Wei Bao, Hongyan Yang, Chengmei Xie, Chen Huang, Jun Wang   +12 more
wiley   +1 more source

Correction: Correlation analysis between plasma concentration of nilotinib and clinical efficacy and safety in patients with chronic myeloid leukemia: a single-center retrospective cohort study. [PDF]

Front Pharmacol
Liu Y, Lin T, Zhao B, Li Y, Zheng P.
europepmc   +2 more sources

Correction: Tosic et al. High Expression Levels of the Long Non-Coding RNAs Lnc-IRF2-3 and Lnc-KIAA1755-4 Are Markers of Poor Prognosis in Chronic Lymphocytic Leukemia. <i>Int. J. Mol. Sci.</i> 2025, <i>26</i>, 1153. [PDF]

Int J Mol Sci
Tosic N, Tomic Vujovic K, Vukovic V, Kotur N, Stankovic B, Marjanovic I, Antic D, Sarac S, Bibic T, Ivanovic J, Zukic B, Karan-Djurasevic T.   +11 more
europepmc   +1 more source